Anti-idiotypic Patents (Class 424/131.1)
  • Patent number: 11994519
    Abstract: The present invention relates to biomarkers associated with multiple sclerosis (MS), particular GLX molecules, and teven more particular GLX-related glycosaminoglycans (GAGs) and GLX-related proteoglycans (PGs).
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 28, 2024
    Assignee: GLX Analytix ApS
    Inventors: Brian William Della Valle, Casper Hempel, Marie Agnete Larsen
  • Patent number: 11865091
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 9, 2024
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ralf Linker
  • Patent number: 11827719
    Abstract: The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: November 28, 2023
    Assignees: HOBIT GENOMIX, INC., NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT
    Inventors: Hirohisa Saito, Kenji Matsumoto, Hideaki Morita, Go Ichien, Yasuhiko Koezuka, Kimishige Ishizaka
  • Patent number: 11713922
    Abstract: Lyophilization methods for preparing protein formulations for long-term storage at room temperature or improved stability at refrigeration storage are provided. Specifically, the present application provides lyophilization methods to obtain a target percentage of residual moisture of a lyophilized product, such as 3-5% residual moisture. The secondary drying of the lyophilization can be conducted under controlling rate of desorption under a temperature which is similar to the shelf temperature of the primary drying. Alternatively, the lyophilization can be conducted without a distinguished secondary drying step.
    Type: Grant
    Filed: November 11, 2022
    Date of Patent: August 1, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Xiaolin Tang, Mary Kleppe, Ravi Chari, Franco Tzul
  • Patent number: 11672865
    Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: June 13, 2023
    Assignee: Comera Life Sciences, Inc.
    Inventors: David S. Soane, Philip Wuthrich, Rosa Casado Portilla, Robert P. Mahoney, Mark Moody
  • Patent number: 11660343
    Abstract: The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: May 30, 2023
    Assignee: Comera Life Sciences, Inc.
    Inventors: David S. Soane, Philip Wuthrich, Rosa Casado Portilla, Robert P. Mahoney, Mark Moody
  • Patent number: 11633476
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 25, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, Yogita Krishnamachari
  • Patent number: 11439682
    Abstract: Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the C?mx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: September 13, 2022
    Assignee: Oneness Biotech Co., Ltd.
    Inventors: Kung-Ming Lu, Nien-Yi Chen, Tien-Tien Cheng
  • Patent number: 11434286
    Abstract: Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: September 6, 2022
    Assignee: Genentech Inc.
    Inventors: ChinYu Lin, Theodore A. Omachi, Ryan P. Owen, Karl Yen, Yanan Zheng, Kendra Debusk
  • Patent number: 11389477
    Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 19, 2022
    Assignee: ELIAZ THEREAPEUTICS, INC.
    Inventor: Isaac Eliaz
  • Patent number: 11389478
    Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 19, 2022
    Assignee: ELIAZ THEREAPEUTICS, INC.
    Inventor: Isaac Eliaz
  • Patent number: 11376332
    Abstract: Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologies, including at least cells, for example. The methods employ targeted delivery by employing at least one ALCAM-binding moiety on the therapeutic, diagnostic or interventional moiety to be delivered. In specific cases, the ALCAM-binding moiety is present on or with the therapeutic moiety in multiple iterations. In certain embodiments, the ALCAM-binding moiety comprises at least one SRCR domain from CD6 and a stalk, such as from CD6, of the secretable or molecular form thereof.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 5, 2022
    Assignee: Baylor College of Medicine
    Inventors: Nabil M. Ahmed, Hebatalla S. Samaha, Antonella Pignata, Kristen Fousek
  • Patent number: 11369687
    Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 28, 2022
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 11324834
    Abstract: Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: May 10, 2022
    Assignee: IGF Oncology, LLC
    Inventors: Hugh McTavish, Arkadiusz Z. Dudek
  • Patent number: 11273205
    Abstract: The present disclosure relates to a pharmaceutical composition, which comprises an IL-15 protein complex and a citrate buffer solution. In addition, the pharmaceutical composition may also comprise a sugar and a non-ionic surfactant. The pharmaceutical composition in the present disclosure demonstrates a high degree of stability even after being stored at 2-8° C. for several months.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: March 15, 2022
    Assignees: JIANGSU HENGRUI MEDICINE CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
    Inventors: Tingting Wu, Hao Li, Xun Liu
  • Patent number: 11173213
    Abstract: A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent in a buffer to reduce interchain disulfides, and (ii) a step of reacting drug linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the reaction temperature in the step (i) is ?10° C. to 10° C., and the average number of bound drugs in the produced antibody-drug conjugate composition is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, in the produced antibody-drug conjugate composition is 50% or more; and an antibody-drug conjugate composition, wherein the content of antibody-drug conjugates wherein the average number of bound drugs is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, is 50% or more.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 16, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shigeru Noguchi, Ken Sakurai, Daisuke Okajima
  • Patent number: 10870694
    Abstract: The present invention comprises methods of using a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69 to treat B-cell disorders.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 22, 2020
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventor: Wayne A. Marasco
  • Patent number: 10792347
    Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: October 6, 2020
    Assignee: Alternative Extracts Inc.
    Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
  • Patent number: 10694761
    Abstract: The invention provides a novel chocolate mass which has a glycemic index of less than 29 (GI<29) and of which the content of added sugar comprises at least 10% galactose and in addition a content of iosmaltulose and/or tagatose. The chocolate mass additionally has a content of vitamin E in the form of a tocotrienol-tocopherol mixture from natural sources, wherein the content of tocotrienols in the chocolate mass is greater than the content of tocopherols.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: June 30, 2020
    Inventor: Johannes Coy
  • Patent number: 10696741
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: June 30, 2020
    Assignee: argenx BVBA
    Inventors: Christophe Frederic Jerome Blanchetot, Birgitte Ursø, Tine Skak-Nielsen, Malene Bertelsen, Sebastian Van Der Woning, Michael Saunders, Johannes Joseph Wilhelmus De Haard
  • Patent number: 10561722
    Abstract: Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response. The compositions and methods can be used to provide a protective immunity against a disease, such as an infection of one or more subtypes of Ebola and Marburg filoviruses, in humans.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: February 18, 2020
    Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human Services
    Inventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Benoit Christophe Stephan Callendret, Macaya Julie Douoguih, Lucy A. Ward
  • Patent number: 10513540
    Abstract: Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: December 24, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Richard S. Blumberg, Vijay K. Kuchroo, Yu-Hwa Huang, Chen Zhu, Ana C. Anderson
  • Patent number: 10465005
    Abstract: Certain embodiments of the disclosure relate to targeted binding agents that specifically bind to JAM-like protein and therein inhibit epithelial damage. Although it is not intended that embodiments of the disclosure be limited by any particular mechanism, it is believed that a possible mechanism by which this can be achieved may include, but are not limited to, either inhibition of binding of JAML to the CAR, inhibition of JAML induced CAR signaling, or increased clearance of JAML from the body of a subject, therein reducing the effective concentration of soluble JAML. In certain embodiment, the specific binding agent is a fully human antibody or chimera that specifically binds to human JAML, such as the JAML D1, and prevents JAML binding to CAR. Certain embodiments of the disclosure contemplate antibodies comprising human IgG type, e.g., IgG1, IgG2, IgG3, and IgG4.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 5, 2019
    Assignee: Emory Patent Group
    Inventors: Charles A. Parkos, Dominique A. Weber
  • Patent number: 10466251
    Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: November 5, 2019
    Assignee: BIOGEN MA INC.
    Inventor: Theodore A. Yednock
  • Patent number: 10392444
    Abstract: The present disclosure relates to a method for inhibiting cancer tumor growth in a patient by administering to the patient a therapeutic monoclonal antibody specific for a tumor associated antigen in combination with at least one immunostimulatory compound, and at least one immune homeostatic checkpoint inhibitor. Also disclosed are uses, compositions and kits thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: August 27, 2019
    Assignee: Oncoquest, Inc.
    Inventors: Ragupathy Madiyalakan, Christopher F Nicodemus
  • Patent number: 10301394
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • Patent number: 10286087
    Abstract: Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: May 14, 2019
    Assignee: UNIQURE IP B.V.
    Inventor: Valerie Ferreira
  • Patent number: 10253102
    Abstract: The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: April 9, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jesper Gromada, Panayiotis Stevis, Judith Altarejos
  • Patent number: 10188760
    Abstract: The present technology comprises methods for regulating an the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. Methods of the present technology comprise both the negative and positive modulation of CEACAM1 protein function.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: January 29, 2019
    Inventor: Gal Markel
  • Patent number: 10183078
    Abstract: Disclosed herein are drug delivery molecules that comprise a ligand that targets a cell surface molecule; a membrane penetration domain; and a payload binding domain; and pharmaceutical compositions comprising the same. Also disclosed are methods of treating cancer, inhibiting the progression of cancer, preventing cancer metastasis, and delivering a therapeutic compound to the brain in a subject in need thereof, the methods comprising identifying a subject in need thereof; providing a composition comprising the drug delivery molecule as disclosed herein; and administering an effective amount of the composition to the subject.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: January 22, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 10144777
    Abstract: The present invention is related to a B-lymphocyte targeting agent for use in a method for the treatment or diagnosis of cardiac insufficiency. Furthermore, it is related to a composition comprising such B-lymphocyte targeting agent and methods for determining whether a patient suffering from cardiac insufficiency is amenable to the use of the B-lymphocyte targeting agent for its treatment.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: December 4, 2018
    Assignee: Charité—Universitätsmedizin Berlin
    Inventors: Carsten Tschöpe, H. P. Schultheiss, Felicitas Escher, Hans-Dieter Volk, Petra Reinke
  • Patent number: 10118962
    Abstract: Processes and methods of purifying or separating Single Domain Antigen Binding (SDAB) molecules that include one or more single binding domains (e.g., one or more nanobody molecules), substantially devoid of a complementary antibody domain and an immunoglobulin constant region, using Protein A-based affinity chromatography, are disclosed.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: November 6, 2018
    Assignee: Ablynx N.V.
    Inventors: Paul R. Brown, Scott Andreas Tobler, Andrew M. Wood, Austin Wayne Boesch
  • Patent number: 10000576
    Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: June 19, 2018
    Assignee: Zymeworks Inc.
    Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
  • Patent number: 9803014
    Abstract: A novel method to reduce B-cell lymphoma cell migration to and engraftment of the spleen in patients with JAM-C positive B-cell lymphomas is described. In certain aspects, a method for identifying and treating JAM-C positive B-cell lymphoma patients with anti-JAM-C antibodies is provided. Recombinant antibody molecules that specifically bind to JAM-C are also disclosed.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: October 31, 2017
    Assignee: Research Development Foundation
    Inventors: Beat Imhof, Christiane Ody, Thomas Matthes, Carmen Donate
  • Patent number: 9795618
    Abstract: Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: October 24, 2017
    Assignee: University of Cincinnati
    Inventors: Fred D. Finkelman, Marat V. Khodoun, Suzanne C. Morris
  • Patent number: 9783613
    Abstract: In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fc? receptor.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: October 10, 2017
    Assignee: IGEM Therapeutics Limited
    Inventors: Sophia Karagiannis, Andrew Beavil, Frank Nestle
  • Patent number: 9580504
    Abstract: Methods for treating specific populations of cancer patients, specifically patients suffering from cancer who undergo stem cell transplantation and were classified as positive by a pre-transplant metabolic imaging, by administering to the subject a therapeutically effective amount of a pidilizumab monoclonal antibody.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: February 28, 2017
    Assignee: CureTech Ltd.
    Inventors: Rinat Rotem-Yehudar, Michael Schickler
  • Patent number: 9573995
    Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 21, 2017
    Assignee: SCHOLAR ROCK, INC.
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Marie Straub
  • Patent number: 9527924
    Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: December 27, 2016
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • Patent number: 9221911
    Abstract: The disclosure relates to a protein composed of a first polypeptide or polypeptide domain having a first specific binding activity for Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) expressed on a T-cell cell surface and a second specific binding activity for Glucose Transporter 2 (GLUT2) or an extracellular ectodomain thereof expressed on a pancreatic ?-cell surface, wherein binding of the first polypeptide or polypeptide domain to CTLA-4 induces a CTLA-4 specific agonist response in the T-cell, and binding of the second polypeptide or polypeptide domain to GLUT2 or an ectodomain thereof does not inhibit GLUT2 glucose transporter function, wherein said agonist response in the T-cell induces a response that reduces immunoreactivity against pancreatic ?-cells.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 29, 2015
    Inventors: Bellur S. Prabhakar, Chenthamarakshan Vasu, Palash Bhattacharya
  • Patent number: 9125893
    Abstract: The present invention relates to a highly concentrated solution preparation of antagonistic anti-CD40 antibody, in which occurrence of turbidity or insoluble foreign matter attributed to antibodies is suppressed to a level equivalent to that of the conventional low-concentration lyophilized preparation.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: September 8, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Ryosuke Endo, Tomoyoshi Ishikawa, Hiroyuki Suetomo
  • Patent number: 9102731
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 11, 2015
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Patent number: 9101559
    Abstract: The present invention is directed to methods of preventing central nervous system leukemia, treating T-cell acute lymphoblastic leukemia, and treating immune system disorders associated with CCR7-CCL19 mediated signaling. Suitable therapeutic agents for inhibiting CCR7-CCL19 signaling and methods of identifying additional therapeutic agents useful in the methods of the present invention are also disclosed.
    Type: Grant
    Filed: May 10, 2010
    Date of Patent: August 11, 2015
    Assignee: New York University
    Inventors: Iannis Aifantis, Silvia Buonamici
  • Patent number: 9102722
    Abstract: Provided herein are antibodies that bind to Repulsive Guidance Molecule a (RGMa) and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: August 11, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
  • Publication number: 20150147314
    Abstract: Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 28, 2015
    Inventors: Wilfred Jefferies, Reinhard Gabathuler
  • Publication number: 20150132286
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 14, 2015
    Inventors: Bruno DOMON, Ian MCCAFFREY, Vaibhav NARAYAN, Scott PATTERSON
  • Publication number: 20150132287
    Abstract: The present invention is directed to methods for modulating the Th/Th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the expression, or the activity of leptin in a subject sufficient to modulate the Th1/Th2 cell balance toward anti-inflammatory cytokine producing cells. The invention is also directed to methods of treatment of an immune-related disorder in a subject comprising decreasing the amount, the expression, or the activity of leptin in the subject sufficient to treat the immune-related disorder.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Applicant: ENZO THERAPEUTICS, INC. C/O ENZO BIOCHEM, INC.
    Inventors: YARON ILAN, ERAN ELINAV
  • Publication number: 20150125442
    Abstract: Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 7, 2015
    Inventors: Steven J. Burden, Wei Zhang, Maartje Huijbers, Johannes J. Verschuuren, Silvère M. van der Maarel
  • Patent number: 9017673
    Abstract: The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-?3 aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.
    Type: Grant
    Filed: June 11, 2004
    Date of Patent: April 28, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Michèle Floc'h Baudy, Olivier Busnel, Sylviane Muller
  • Publication number: 20150056182
    Abstract: The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. Moreover, they found that by using this characteristic and by further using antigen-binding molecules having an ion-dependent antigen-binding activity, elimination of the antigens can further be accelerated and the above problem can be solved.
    Type: Application
    Filed: November 30, 2012
    Publication date: February 26, 2015
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoyuki Igawa, Naoka Hironiwa